RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Exclusion Criteria

• •CNV or macular edema in the study eye secondary to any causes other than AMD.
• •Subfoveal fibrosis or atrophy in study eye.
• •Participants who have had a prior vitrectomy.
• •Active or history of retinal detachment in the study eye.
• •History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product (IP), other than anti-VEGF therapy, in the 6 months prior to study entry.
• •Received any gene therapy.
• •Any condition preventing visualization of the fundus or VA improvement in the study eye, eg, cataract.
• •History of intraocular surgery in the study eye within 12 weeks of study entry.
• •Receipt of any IP within 30 days of study entry or 5 half-lives of the IP.
• •Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within 6 months of study entry.
• •Cohorts 1 - 5 only: Uncontrolled glaucoma in the study eye.
• •COHORT 6 AND 7 ONLY:
• •Active or history of glaucoma or ocular hypertension (steroid-induced ocular hypertension (Cohort 7 only)) in the study eye.
• •Certain OCT characteristics including: Large Pigment Epithelial Detachments (PED), clinically significant Epiretinal Membrane (ERM) in the study eye at Visit 1.